Comparative Evaluation of Dashamula saindhavaa Sarpi as Nasya (nasal administration) versus Oral administration in the Management of Ardhavabhedaka (~Migraine): A Randomized Parallel Group Clinical Study

IF 0.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Gaurav Sinha, Kalpana Patni
{"title":"Comparative Evaluation of Dashamula saindhavaa Sarpi as Nasya (nasal administration) versus Oral administration in the Management of Ardhavabhedaka (~Migraine): A Randomized Parallel Group Clinical Study","authors":"Gaurav Sinha, Kalpana Patni","doi":"10.47552/ijam.v14i3.3391","DOIUrl":null,"url":null,"abstract":"Ardhavabhedaka is described as one of the eleven types of Shiroroga (headache disorders) in all Ayurvedic classical texts. It is a disease in which there is acute pain in half of the head, laterals of the neck, temporal region, ear and eyes. Based on the similarity in etiology, pathology, symptoms and treatment principles Ardhavabhedaka can be very well connected with migraine. As per the International Headache Society (IHS), Migraine accounts for 16% of all primary headaches. As per WHO, Migraine prevalence and incidence of the attack suggest that migraine attacks around 3000 persons per million populations every day globally. Aim of Study: To compare the effect of Dashmula saindhavaa Sarpi Nasya and Oral in the Management of Ardhavabhedaka wsr to Migraine. Material and Methods: Total of 68 patients of age group 16 to 60 years of either sex were enrolled based on headache as the chief complaint. After screening via a Pre-diagnostic questionnaire (IHS), 24 patients were excluded and 44 patients recruited were randomly divided into two groups, group A received Dashmula saindhavaa Sarpi nasya, 6 drops in each nostril for 7 days, repeated after intervals of 1 week (four cycles) and Group B received Dashmula saindhava Sarpi orally 12 grams/day in two divided doses for 2 months. The assessment was done based on 4 point grading score of Clinical symptoms of Ardhavabhedaka (Migraine). Result: Overall effect of therapy shows that in Group A 05.00% had the complete cure, 50.00% of patients had marked improvement and 40.00% had moderate improvement whereas, in Group B, 05.88% had the complete cure, 35.29% of patients had marked improvement and 35.29% had moderate improvement. Both groups showed highly significant results (p = >0.001) in severity, duration, and frequency and various parameters of Ardhavabhedaka with more percentage improvement in Group A i.e., with Nasya therapy. Conclusion: Clinical assessment of Dashmula saindhava Sarpi nasya and as oral therapy on different parameters of Ardhavabhedaka showed that both are effective and safe.","PeriodicalId":13751,"journal":{"name":"International Journal of Ayurvedic Medicine","volume":"17 1","pages":"0"},"PeriodicalIF":0.1000,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Ayurvedic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47552/ijam.v14i3.3391","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Ardhavabhedaka is described as one of the eleven types of Shiroroga (headache disorders) in all Ayurvedic classical texts. It is a disease in which there is acute pain in half of the head, laterals of the neck, temporal region, ear and eyes. Based on the similarity in etiology, pathology, symptoms and treatment principles Ardhavabhedaka can be very well connected with migraine. As per the International Headache Society (IHS), Migraine accounts for 16% of all primary headaches. As per WHO, Migraine prevalence and incidence of the attack suggest that migraine attacks around 3000 persons per million populations every day globally. Aim of Study: To compare the effect of Dashmula saindhavaa Sarpi Nasya and Oral in the Management of Ardhavabhedaka wsr to Migraine. Material and Methods: Total of 68 patients of age group 16 to 60 years of either sex were enrolled based on headache as the chief complaint. After screening via a Pre-diagnostic questionnaire (IHS), 24 patients were excluded and 44 patients recruited were randomly divided into two groups, group A received Dashmula saindhavaa Sarpi nasya, 6 drops in each nostril for 7 days, repeated after intervals of 1 week (four cycles) and Group B received Dashmula saindhava Sarpi orally 12 grams/day in two divided doses for 2 months. The assessment was done based on 4 point grading score of Clinical symptoms of Ardhavabhedaka (Migraine). Result: Overall effect of therapy shows that in Group A 05.00% had the complete cure, 50.00% of patients had marked improvement and 40.00% had moderate improvement whereas, in Group B, 05.88% had the complete cure, 35.29% of patients had marked improvement and 35.29% had moderate improvement. Both groups showed highly significant results (p = >0.001) in severity, duration, and frequency and various parameters of Ardhavabhedaka with more percentage improvement in Group A i.e., with Nasya therapy. Conclusion: Clinical assessment of Dashmula saindhava Sarpi nasya and as oral therapy on different parameters of Ardhavabhedaka showed that both are effective and safe.
Dashamula saindhavaa Sarpi作为鼻窦给药与口服给药治疗Ardhavabhedaka(~偏头痛)的比较评价:随机平行组临床研究
在所有阿育吠陀经典文献中,Ardhavabhedaka被描述为11种Shiroroga(头痛疾病)之一。这种疾病的症状是头部的一半、颈部侧面、颞区、耳朵和眼睛都有剧烈疼痛。基于在病因、病理、症状和治疗原理上的相似性,Ardhavabhedaka可以很好地与偏头痛联系起来。根据国际头痛协会(IHS)的数据,偏头痛占所有原发性头痛的16%。根据世卫组织的数据,偏头痛的患病率和发病率表明,全球每天每百万人中约有3000人患有偏头痛。研究目的:比较中药丹参与口服丹参治疗偏头痛的疗效。材料与方法:以头痛为主诉的患者共68例,年龄16 ~ 60岁,男女不限。通过预诊断问卷(IHS)筛选,排除24例患者,纳入44例患者,随机分为两组,a组患者给予Dashmula saindhava Sarpi,每个鼻孔6滴,连续7天,每隔1周重复一次(4个周期);B组患者口服Dashmula saindhava Sarpi 12克/天,分两次服用,连续2个月。根据Ardhavabhedaka(偏头痛)临床症状4分评分进行评估。结果:综合治疗效果:A组患者完全治愈率为05.00%,显著改善率为50.00%,中度改善率为40.00%;B组患者完全治愈率为05.88%,显著改善率为35.29%,中度改善率为35.29%。两组在Ardhavabhedaka的严重程度、持续时间、频率和各种参数方面均显示出高度显著的结果(p = >0.001), A组(即使用Nasya治疗)的改善百分比更高。结论:经临床评价,丹参和丹参作为口服药物治疗丹参的不同参数均有效、安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Ayurvedic Medicine
International Journal of Ayurvedic Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
50.00%
发文量
87
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信